| Literature DB >> 34853355 |
Khalid El Bairi1, Harry R Haynes2,3, Elizabeth Blackley4, Susan Fineberg5, Jeffrey Shear6, Sophia Turner7, Juliana Ribeiro de Freitas8, Daniel Sur9, Luis Claudio Amendola10, Masoumeh Gharib11, Amine Kallala12, Indu Arun13, Farid Azmoudeh-Ardalan14, Luciana Fujimoto15, Luz F Sua16, Shi-Wei Liu17, Huang-Chun Lien18, Pawan Kirtani19, Marcelo Balancin20, Hicham El Attar21, Prerna Guleria22, Wenxian Yang23, Emad Shash24, I-Chun Chen25,26, Veronica Bautista27, Jose Fernando Do Prado Moura28, Bernardo L Rapoport29,30, Carlos Castaneda31,32, Eunice Spengler33, Gabriela Acosta-Haab34, Isabel Frahm35, Joselyn Sanchez36, Miluska Castillo36, Najat Bouchmaa37, Reena R Md Zin38, Ruohong Shui39, Timothy Onyuma40, Wentao Yang39, Zaheed Husain41, Karen Willard-Gallo42, An Coosemans43, Edith A Perez44, Elena Provenzano45, Paula Gonzalez Ericsson46, Eduardo Richardet47, Ravi Mehrotra48, Sandra Sarancone49, Anna Ehinger50, David L Rimm51, John M S Bartlett52,53,54, Giuseppe Viale55, Carsten Denkert56, Akira I Hida57, Christos Sotiriou58, Sibylle Loibl59, Stephen M Hewitt60, Sunil Badve61, William Fraser Symmans62, Rim S Kim63, Giancarlo Pruneri64, Shom Goel4,65, Prudence A Francis65,66, Gloria Inurrigarro67, Rin Yamaguchi68, Hernan Garcia-Rivello69, Hugo Horlings70, Said Afqir71, Roberto Salgado4,72, Sylvia Adams73, Marleen Kok74, Maria Vittoria Dieci75,76, Stefan Michiels77, Sandra Demaria78, Sherene Loi4,65.
Abstract
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.Entities:
Year: 2021 PMID： 34853355 PMCID： PMC8636568 DOI： 10.1038/s41523-021-00346-1
Source DB: PubMed Journal: NPJ Breast Cancer ISSN： 2374-4677